Medicinal chemistry and project leadership on modulating RNA processing for the treatment diseases with significant unmet needs

Enabling the next generation of CNS drug discovery targets for Sage Therapeutics

• Director and principle contributor to discovery of Turing’s first in house derived development candidate. This compound is a highly selective T. gondii DHFR inhibitor for the treatment of Toxoplasmosis • Responsible for compound design, candidate nomination, preclinical development and cGMP API manufacturing (First human dose targeted 4Q 2017) • Discovered and nominated a backup for the treatment of Toxoplasmosis June 2017• Expanded DHFR chemistry platform and identified advanced leads for other apicomplexan parasite DHFRs as potential novel treatments for neglected parasitic infections• Directed CDPK-1 lead optimization to substantially improve properties of early literature leads and establish intellectual property • Managed and developed relationships with CROs, academic collaborators and consultants to successfully prosecute projects• Responsible for securing intellectual property covering Turing’s novel chemical matter across all programs• Established and maintained corporate compound and biology database using Scilligence platform• Represented Turing’s discovery research at international Scientific advisory board meetings and externally to support Medical Affairs team

Principal Scientist (Chemistry and Neuroinflammation Disease Biology Unit)• P2X7 receptor antagonist project leader (2012 – present). Leader of a global core project team consisting of representatives from chemistry, biology, toxicology, mol pharm, adme/pk, intellectual property and clinical. With direct accountability over results, sharpened my skills to lead without formal authority. Progressed project through various stage gates into advanced research for neuropathic pain. • P2X7 receptor antagonist program Med Chem lead (2010 – 2012). Managed five direct reports and FTE based chemistry CROs on lead optimization of three chemical series. • P2X4 receptor antagonist project and chemistry lead (2014 – present) • mGluR5 PAM team member (2009 – 2010)

Oversight and member of the PDE 10 inhibitor program chemistry team. Participated in due diligence exercises leading to program partnership with Amgen. Successfully utilized structure-based and creative chemistry approaches to solve difficult cross-reactivity issues to obtain highly potent leads with greater than 1000-fold selectivity. Led MEM 1414 clinical EEG Ph1 project team. Project successfully implemented and completed with results supporting continued MEM 1414 development. Provided significant input into the clinical plan, worked with CROs to prepare placebo tablets, release active tablets and provided all appropriate CMC documentation to support study. Member of the MEM 1414 Ph2 clinical team and responsible for CMC activities. Chemistry project leader for the PDE4 Inhibitor program and project leader for Roche collaboration. Successfully identified structurally diverse backup PDE4 compounds and advanced to preclinical nomination stage.

Chemistry project team leader for PDE4 project. Led chemistry team in lead optimization process culminating in the selection of a compound (MEM 1414) for development.

Project leader for the GlyT-1 inhibitor program. Led a team of Allelix scientists and coordinated all scientific interactions with Janssen Research Foundation, the program partner, with the objective of moving the program from the discovery stage through the clinical candidate selection process. A compound was selected for development from these efforts. Involved in management decision making regarding the chemistry group (6 chemists)